IK Partners, a leading European private equity firm, acquired a majority stake in Cinerius Group. Cinerius is a Swiss headquartered leading platform for independent wealth managers in German-speaking European regions. The previous majority investor Summit Partners and the management continue to hold a significant stake in the group. Bär & Karrer acted as Swiss legal […]
Baker McKenzie has advised the Swiss family-owned company Planzer, on the acquisition of Quickpac and Quickmail. Quickpac is a tech start-up for smaller parcels in German-speaking areas of Switzerland, it relies on modern IT applications
Credit Mutuel Equity is partnering with somnOO to support the expansion of their hotel portfolio and management platform. This includes providing growth capital and allowing somnOO’s management team to take a stake in the
EraCal Therapeutics AG (“EraCal”), a Swiss biotech start-up company focusing on the fight of obesity, has licensed its main asset to Novo Nordisk for a total amount of EUR 235m in a collaboration and license
Intrum AB (publ) has agreed to sell a material portion of its investment portfolio to affiliates of Cerberus Capital Management L.P. for more than EUR 1 billion. The transaction involves over 10,000 portfolios with a nominal
Niederer Kraft Frey has advised MVM Partners on its investment in icotec. Icotec is a leading company in the field of innovative spinal tumor implants and is commercialising groundbreaking BlackArmor Carbon/PEEK products that may
UBS Switzerland AG has successfully completed its issuance of Covered Bonds under its covered bond program in an aggregate principal amount of CHF 450 m, consisting of CHF 180 m 1.5427% Covered Bonds due January 2027 and CHF 270 m 1.7150%
Schellenberg Wittmer has advised AXA Investment Managers Schweiz on the merger of its three real estate funds. The fund merger was approved by FINMA as well as the fund contract of the soon to be
Barry Callebaut tapped the Swiss market for the first time successfully issuing two tranches of CHF bonds in the total aggregate amount of CHF 600 million. The first tranche
Baker McKenzie has advised Bristol-Myers Squibb Company (“BMS”) on its investment into GlycoEra AG (“GlycoEra”) in its extended series A financing round. In its series A financing round, GlycoEra raised funds to further advance its
